Lupus Nephritis Drugs

Aug 10, 2026

Summary Lupus nephritis treatment is entering a new phase, shifting from broad immunosuppressants to targeted biologics, with BENLYSTA (belimumab) and GAZYVA (obinutuzumab) emerging as key competitors. BENLYSTA is the established benchmark, with over a decade of clinical use in SLE and approvals for lupus ne...

Nov 03, 2025

Roche’s GAZYVA FDA approval has already rewritten the lupus nephritis playbook — it turned a long-standing oncology B-cell drug into a validated, kidney-saving option. It proved that aggressive B-cell targeting can materially boost complete renal responses when added to standard therapy. The GAZYVA approval (driven...